News

NICE and IQWiG nix Benlysta
Enlarge image

PolicyGermanyUK

NICE and IQWiG nix Benlysta

07.05.2012 - Healthcare cost watchdogs are not convinced by GSK’s Lupus drug Benlysta: British NICE and German IQWiG have recommended against the drug.

Cologne/London – “No additional benefit documented” – With these harsh words the German Institute for Quality and Efficiency in Health Care (IQWiG) rebuffed GSK’s Lupus antibody belimumab (Benlysta). Under the new, tougher German reimbursement regime, the Institute evaluates newly approved drugs for their additional medical benefit and issues a draft benefit assessment. That decision could mean a large, forced discount to Benlysta's price on the German market.

Although Benlysta is the first new treatment for lupus for decades, it has been slow to take off so far. Negative assessments as form NICE and IQWiG won’t help to improve the situation. GSK, Britain's biggest drugmaker, said on Thursday that the judgment from IQWiG was "completely inexplicable from a medical point of view and disregards genuine progress in therapy".

The drug was discovered by Human Genome Science (HGS) and developed jointly with GSK. In mid-April GSK offered to acquire the US-based biotech company for $2,3b. HGS’ management refused the offer, stating, it “does not reflect value inherent in company“.

„Their case for a higher bid seems to be based on the market potential of Benlysta, but the arguing has begun over how realistic those hopes are“, stated Drug discovery Chemist Derek Lowe. Besides Benlysta, HGS might bank on albiglutide (Diabetes) and darapladib (Artheroslcerosis), which are currently undergoing Phase III trials, which could bring significant revenues if approved.

http://www.european-biotechnology-news.com/news/news/2012-02/nice-and-iqwig-nix-benlysta.html

2014EU

19.12.2014 We took a look back at 2014: which European Biotechnology News stories topped the charts this year?

R&DEUBelgium

18.12.2014 IMI has launched a €115m call for proposals involving a project in collaboration with the Bill and Melinda Gates Foundation to improve vaccines against whopping cough in children.

PoliticsEUPolandItalySpainUK

16.12.2014 Two consortia combined of 144 European companies, research institutes and universities have been selected for funding by the EIT in the areas of health and raw materials. Both clusters are set to acquire €1.1bn over the next seven years.

M&ALuxembourg

11.12.2014 Luxembourg bio-analytical testing company Eurofins Scientific has signed an agreement to acquire Boston Heart Diagnostics Corp. for an initial €112m.

StudySwitzerlandEU

10.12.2014 When it comes to the biggest investors in Research and Development (R&D) Swiss pharma top dogs Novartis and Roche have defended their positioning among the top ten companies worldwide – according to a recently published EU study.

FinancingUKSpain

09.12.2014 British drug delivery specialist Midatech Pharma plc floated on the London stock market. It is the third biotech IPO on the AIM market this year.

CooperationAustria

05.12.2014 Austrian contract research company VTU has entered into a development and commercialisation agreement with US company RCT. The partners want to combine both companies' Pichia pastoris protein production technologies under VTU's roof.

FinancingDenmark

03.12.2014 Danish biotech pharma Ascendis has successfully completed a €48m Series D financing round. The funding is expected to support its late-stage clinical trials to push its lead drug into Phase III trials.

Events

All Events

Current issue

All issues

Product of the week

Products